Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mullen, C. A.
Right arrow Articles by Blaese, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mullen, C. A.
Right arrow Articles by Blaese, R. M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Splenectomy and/or bone marrow transplantation in the management of the Wiskott-Aldrich syndrome: long-term follow-up of 62 cases

CA Mullen, KD Anderson and RM Blaese

Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

This study describes the effects of two major treatment options, splenectomy and/or bone marrow transplantation, on the natural history of the Wiskott-Aldrich (WAS) syndrome. The records of 62 patients with the WAS evaluated at the National Institutes of Health Clinical Center from 1966 to 1992 were reviewed. Nineteen patients were treated with bone marrow transplantation (BMT) and the results were largely dependent on the source of the graft. Twelve of 12 patients receiving HLA-matched sibling marrow achieved satisfactory immunologic and hematologic reconstitution. By contrast, only 2 of 7 patients receiving haploidentical, parental, or matched unrelated marrow survived more than 1 year after BMT. Thirty-nine patients who lacked suitable bone marrow donors early in their course underwent splenectomy for management of their thrombocytopenia; most received prophylactic antibiotics to minimize the risk of sepsis. Nearly all these patients achieved normal platelet counts and the rate of serious bleeding was reduced nearly sevenfold. Median survival in the untransplanted splenectomy group was 25 years, compared with less than 5 years in unsplenectomized patients. We conclude that HLA-matched sibling donor BMT is the treatment of choice for patients with WAS and that splenectomy and daily prophylactic antibiotics provide a significant survival advantage to those boys without a matched sibling donor. Splenectomy should probably be used in preference to unmatched BMT until results with alternative donor BMT significantly improve or gene therapy becomes available.

Volume 82, Issue 10, pp. 2961-2966, 11/15/1993
Copyright © 1993 by The American Society of Hematology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
H. Falet, M. P. Marchetti, K. M. Hoffmeister, M. J. Massaad, R. S. Geha, and J. H. Hartwig
Platelet-associated IgAs and impaired GPVI responses in platelets lacking WIP
Blood, November 19, 2009; 114(21): 4729 - 4737.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. L. Balduini and J. G. Drachman
Role of splenectomy in inherited thrombocytopenias
Blood, August 15, 2004; 104(4): 1227 - 1227.
[Full Text] [PDF]


Home page
ICVTSHome page
P. Narayan, H. Alwair, and A. J. Bryan
Surgical resection of sequential thoracic aortic aneurysms in Wiskott-Aldrich syndrome
Interactive CardioVascular and Thoracic Surgery, June 1, 2004; 3(2): 346 - 348.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Imai, T. Morio, Y. Zhu, Y. Jin, S. Itoh, M. Kajiwara, J.-i. Yata, S. Mizutani, H. D. Ochs, and S. Nonoyama
Clinical course of patients with WASP gene mutations
Blood, January 15, 2004; 103(2): 456 - 464.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
D. B. Cines, J. B. Bussel, R. B. McMillan, and J. L. Zehnder
Congenital and Acquired Thrombocytopenia
Hematology, January 1, 2004; 2004(1): 390 - 406.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
S. Dupuis-Girod, J. Medioni, E. Haddad, P. Quartier, M. Cavazzana-Calvo, F. Le Deist, G. de Saint Basile, J. Delaunay, K. Schwarz, J.-L. Casanova, et al.
Autoimmunity in Wiskott-Aldrich Syndrome: Risk Factors, Clinical Features, and Outcome in a Single-Center Cohort of 55 Patients
Pediatrics, May 1, 2003; 111(5): e622 - 627.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Falet, K. M. Hoffmeister, R. Neujahr, and J. H. Hartwig
Normal Arp2/3 complex activation in platelets lacking WASp
Blood, August 28, 2002; 100(6): 2113 - 2122.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Yamaguchi, T. Ariga, M. Yamada, D. L. Nelson, R. Kobayashi, C. Kobayashi, Y. Noguchi, Y. Ito, K. Katamura, Y. Nagatoshi, et al.
Mixed chimera status of 12 patients with Wiskott-Aldrich syndrome (WAS) after hematopoietic stem cell transplantation: evaluation by flow cytometric analysis of intracellular WAS protein expression
Blood, July 30, 2002; 100(4): 1208 - 1214.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. S. Strom, X. Li, J. M. Cunningham, and A. W. Nienhuis
Correction of the murine Wiskott-Aldrich syndrome phenotype by hematopoietic stem cell transplantation
Blood, May 29, 2002; 99(12): 4626 - 4628.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. H. Filipovich, J. V. Stone, S. C. Tomany, M. Ireland, C. Kollman, C. J. Pelz, J. T. Casper, M. J. Cowan, J. R. Edwards, A. Fasth, et al.
Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program
Blood, March 15, 2001; 97(6): 1598 - 1603.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
R. H. Buckley
Primary Immunodeficiency Diseases Due to Defects in Lymphocytes
N. Engl. J. Med., November 2, 2000; 343(18): 1313 - 1324.
[Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
A. M Jones and H. B Gaspar
Immunogenetics: changing the face of immunodeficiency
J. Clin. Pathol., January 1, 2000; 53(1): 60 - 65.
[Full Text] [PDF]


Home page
BloodHome page
B. S. Gross, J. I. Wilde, L. Quek, H. Chapel, D. L. Nelson, and S. P. Watson
Regulation and Function of WASp in Platelets by the Collagen Receptor, Glycoprotein VI
Blood, December 15, 1999; 94(12): 4166 - 4176.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. D. Gallego, M. Santamaria, J. Pena, and I. J. Molina
Defective Actin Reorganization and Polymerization of Wiskott-Aldrich T Cells in Response to CD3-Mediated Stimulation
Blood, October 15, 1997; 90(8): 3089 - 3097.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
C. Thomas, G. de Saint Basile, F. Le Deist, D. Theophile, M. Benkerrou, E. Haddad, S. Blanche, and A. Fischer
Correction of X-Linked Hyper-IgM Syndrome by Allogeneic Bone Marrow Transplantation
N. Engl. J. Med., August 17, 1995; 333(7): 426 - 429.
[Full Text] [PDF]


Home page
NEJMHome page
F. S. Rosen, M. D. Cooper, and R. J.P. Wedgwood
The Primary Immunodeficiencies
N. Engl. J. Med., August 17, 1995; 333(7): 431 - 440.
[Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1993 by American Society of Hematology         Online ISSN: 1528-0020